
More than US$ 1.8 billion approved to tackle backsliding, fight health emergencies
Gavi Board approves the African Vaccine Manufacturing Accelerator (AVMA), a financing instrument to US$ 1 billion available to support sustainable vaccine manufacturing in Africa, and other landmark decisions.
Read press releaseMore than US$ 1.8 billion approved to tackle backsliding, fight health emergencies
Gavi Board approves the African Vaccine Manufacturing Accelerator (AVMA), a financing instrument to US$ 1 billion available to support sustainable vaccine manufacturing in Africa, and other landmark decisions.
Read press release
One billion immunised but challenges ahead: read Gavi’s 2022 Annual Progress Report
Welcome to Gavi’s 2022 Annual Progress Report, the second of the 2021–2025 strategic period.
View reportOne billion immunised but challenges ahead: read Gavi’s 2022 Annual Progress Report
Welcome to Gavi’s 2022 Annual Progress Report, the second of the 2021–2025 strategic period.
View report
About our Alliance
As part of its mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines, Gavi has helped vaccinate more than 1 billion children in 78 lower-income countries, averting more than 17.3 million future deaths.
Who we areAbout our Alliance
As part of its mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines, Gavi has helped vaccinate more than 1 billion children in 78 lower-income countries, averting more than 17.3 million future deaths.
Who we are
Our strategy
Gavi's 2021–2025 strategy aims to help immunise 300 million children worldwide with routine vaccines, averting 7–8 million deaths, with a focus on reaching zero-dose children and missed communities.
Read our strategyOur strategy
Gavi's 2021–2025 strategy aims to help immunise 300 million children worldwide with routine vaccines, averting 7–8 million deaths, with a focus on reaching zero-dose children and missed communities.
Read our strategy